1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Pierre Fabre Fights Off Rivals For Rights To Atara's Allogeneic T-Cell Therapy

Tab-Cel Granted Accelerated Assessment By EMA For Rare Cancer

 
• By Kevin Grogan

After paying $45m upfront, the French firm has beaten off considerable competition to seal the European, Middle East and African rights to tabelecleucel which will be filed next month for Epstein-Barr virus-positive post-transplant lymphoproliferative disease.

boxer
Pierre Fabre clinches decision for tab-cel rights • Source: Alamy

Pierre Fabre has moved fast to secure the rights to Atara Biotherapeutics, Inc.'s tabelecleucel, just days after the off-the-shelf T-cell therapy got the green light to be fast-tracked by regulators in Europe.

The privately-owned French group is paying $45m upfront to get the commercialization rights for tabelecleucel (tab-cel) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.